|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
|
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current assets: | ||||||
| Due from Sponsor | ||||||
| Cash and cash equivalents | ||||||
| Prepaid insurance | ||||||
| Prepaid expenses and other current assets | ||||||
| Total current assets | ||||||
| Deferred offering costs | ||||||
| Marketable securities held in Trust Account | ||||||
| Long-term prepaid insurance | ||||||
| TOTAL ASSETS | ||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||
| Current liabilities: | ||||||
| Accrued expenses | ||||||
| Accrued offering costs | ||||||
| Due to related party | ||||||
| Promissory note - related party | ||||||
| Total current liabilities | ||||||
| Deferred underwriting fee payable | ||||||
| Total Liabilities | ||||||
| Class A ordinary shares subject to possible redemption, 17,250,000 at redemption value of $10.44 and $10.27 at June 30, 2026 and December 31, 2025, respectively | ||||||
| Shareholders’ Deficit | ||||||
| Equity value | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Class B Ordinary Shares | ||||||
| Total accumulated deficit | ||||||
| Total Shareholders’ Deficit | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
Loading...
